Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate

Annals of Hematology

Volumn 88, Issue 5, 2009, Pages 433-439

  Fietz, Thomas ^a   Knauf, W U ^a,e   Hanel M ^b   Franke, A ^c   Freund, M ^d   Thiel, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e Oncology Bethanien   (Germany)

Author keywords

High dose methotrexate; Long term results; Primary mediastinal large B cell lymphoma; Prospective multicenter study

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; ITRACONAZOLE; METHOTREXATE; MORPHINE; TENIPOSIDE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; GENE EXPRESSION PROFILING; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LIVER TOXICITY; MEDIASTINAL LARGE CELL LYMPHOMA; MEDIASTINUM DISEASE; MEDIASTINUM MASS; MUCORMYCOSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR REGRESSION; TUMOR VOLUME; VOMITING; ADOLESCENT; AGED; B CELL LYMPHOMA; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; DRUG TOXICITY; FEMALE; MALE; MEDIASTINUM TUMOR; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; DRUG TOXICITY; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; METHOTREXATE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63649134682     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0625-2     Document Type: Article

References (32)

1. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851-862
2. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871-3879
3. Jaffe ES (2001) WHO classification of tumours, pathology and genetics, tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France
4. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL (2007) Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 31(1):106-112
5. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A, Lymphoma/Leukemia Molecular Profiling Project (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106(9):3183-3190
6. Aisenberg AC (1993) Primary large-cell lymphoma of the mediastinum. J Clin Oncol 11(12):2291-2294
7. Kolonic SO, Dzebro S, Kusec R, Planinc-Peraica A, Dominis M, Jaksic B (2006) Primary mediastinal large B-cell lymphoma: A single-center study of clinicopathologic characteristics. Int J Hematol 83(4):331-336
8. Savage KJ (2006) Primary mediastinal large B-cell lymphoma. Oncologist 11(5):488-495
9. Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E, Bocchia M, Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S (2001) Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 86(2):187-191
10. Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F, International Extranodal Lymphoma Study Group (IELSG) (2002) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica 87(12):1258-1264
11. Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 90(2):372-376
12. Sekiguchi N, Nishimoto J, Tanimoto K, Kusumoto S, Onishi Y, Watanabe T, Kobayashi Y, Asamura H, Kagami Y, Matsuno Y, Tobinai K (2004) Primary mediastinal large B-cell lymphoma: A single-institution clinical study in Japan. Int J Hematol 79(5):465-471
13. Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH (2005) Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 130(5):691-699
14. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, Hossfeld D, Buchner T, Koch P, Freund M, Hiddemann W, Maschmeyer G, Heyll A, Aul C, Faak T, Kuse R, Ittel TH, Gramatzki M, Diedrich H, Kolbe K, Fuhr HG, Fischer K, Schadeck-Gressel C, Weiss A, Strohscheer I, Metzner B, Fabry U, Gokbuget N, Volkers B, Messerer D, Uberla K (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87(2):495-508
15. Agresti A, Coull BA (1998) Approximate is better than exact for interval estimation of binomial proportions. Am Stat 52:119-126
16. Simon R (1989) Optimal two stage designs for phase II clinical trials. Control Clin Trials 10:1-10
17. Levitt LJ, Aisenberg AC, Harris NL, Linggood RM, Poppema S (1982) Primary non-Hodgkin's lymphoma of the mediastinum. Cancer 50:2486-2492
18. Trump DL, Mann RB (1982) Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement. Cancer 50:277-282
19. Barth TF, Leithauser F, Joos S, Bentz M, Moller P (2002) Mediastinal (thymic) large B-cell lymphoma: Where do we stand? Lancet Oncol 3(4):229-234
20. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol 17(1):123-130
21. Nath SV, Seymour JF (2005) Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leuk Lymphoma 46(7):1075-1079
22. Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, Bendandi M, Martelli MP, Ascani S, Orcioni GF, Pileri SA, Mandelli F, Tura S (1999) Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 94(10):3289-3293
23. Martelli M, Stefoni V, Cabras G, Cortellazzo S, Brusamolino E, Levis A, Botto B, De Vivo A, Natalino F, Erica F, Foa R, Zinzani PL (2006) Rituximab combined with M/VACOP-B and radiotherapy in primary mediastinal large B-cell lymphoma (PMLBCL): A prospective Italian phase II IIL study. Blood 108 (abstract #4697)
24. Dunleavy K, Pittaluga S, Janik J, Grant N, Steinberg S, Staudt L, Jaffe E, Wilson WH (2005) Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-epoch and overcomes the need for radiation. Blood 106 (abstract #929)
25. Vassilakopoulos TP, Angelopoulou MK, Galani Z, Sachanas S, Katsigiannis A, Vrakidou E, Poziopoulos C, Constantinou N, Repoussis P, Dimopoulou MN, Kokoris SI, Michali E, Dimitriadou EM, Siakantaris MP, Kontopidou FN, Kalpadaki C, Viniou NA, Kyriakou E, Korkolopoulou P, Kyrtsonis MC, Panayiotidis P, Roussou P, Pangalis GA (2006) Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL). Blood 108 (abstract #2745)
26. Muller U, Stahel RA (1993) Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 4(5):399-402
27. Armitage JO (2007) How I treat patients with diffuse large B-cell lymphoma. Blood 110(1):29-36
28. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379-391
29. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117-4126
30. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 15(1):129-133
31. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC (1999) CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 17(8):2479-2485
32. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149-157